Skip to main content
. 2018 May 31;8(5):e018070. doi: 10.1136/bmjopen-2017-018070

Table 1.

A summary table of the meta-analysis

Study Year Country Diseases Case no Stage Sample Assay Cut-off value HR Follow-up (months) Type of miR-17 detection
Chen et al37 2012 China HCC 120 I–IV Tissue qRT-PCR Median RR 46 miR-17–5p
Qun et al27 2013 China Lung cancer 221 I–IV Tissue qRT-PCR Median Given 50 miR-17
Li et al41 2014 China Osteosarcoma 117 I–III Tissue qRT-PCR Median Given 44 miR-17
Lu et al35 2012 China Glioma 108 I–IV Tissue qRT-PCR Mean RR 60 miR-17
Xi et al42 2015 China T-cell lymphoblastic lymphoma 57 III, IV Tissue qRT-PCR Median Given Up to 13 years miR-17
Yu et al40 2012 China Colon cancer 48 I–IV Tissue qRT-PCR Median Given 5–66 miR-17
Manuel et al39 2011 Spain Gastrointestinal cancer 38 I–IV Tissue qRT-PCR Mean Given 38 miR-17
Robaina et al38 2016 Brazil Burkitt lymphoma 41 I–IV Tissue ISH Median Given 69 miR-17
Xu et al36 2014 China Oesophageal squamous cell carcinoma 105 I–IV Tissue qRT-PCR Mean Given 52 miR-17
Jun et al26 2010 Japan Pancreatic cancer 80 I–IV Tissue qRT-PCR Median Given 60 miR-17–5p
Wang et al43 2011 China Gastric cancer 65 I–IV Serum qRT-PCR Median Given 36 miR-17–5p
Zheng et al34 2013 China HCC 96 I–IV Serum qRT-PCR Median Given NG miR-17–5p

HCC, hepatocellular carcinoma; ISH, in situ hybridisation; miR-17, microRNA-17; NG, not given; OS, overall survival; qRT-PCR, quantitative real-time PCR; RR, risk ratio.